Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Oct 1:2018:7270486.
doi: 10.1155/2018/7270486. eCollection 2018.

Lipid and Bile Acid Dysmetabolism in Crohn's Disease

Affiliations
Review

Lipid and Bile Acid Dysmetabolism in Crohn's Disease

Koji Uchiyama et al. J Immunol Res. .

Abstract

Crohn's disease is one of the systemic autoimmune diseases. It commonly affects the small intestine and colon but may involve any portion of the gastrointestinal tract from the mouth to the anus. The most affected area by Crohn's disease is the distal part of the small intestine, in which the bile acid molecules are most efficiently reabsorbed. Bile acids form mixed micelles together with fatty acids, which function as a transport vehicle to deliver fatty acids to the apical membrane of enterocytes for absorption. Therefore, if the terminal ileum is impaired, bile acid malabsorption may occur, which may cause congenital diarrhoea in Crohn's disease. Similarly, the impairment of the terminal ileum also induces fatty acid malabsorption, which may influence the role of fatty acids in Crohn's disease. In contrast, a recent study reported that multidrug resistance protein 1 (MDR1) regulated effector T-cell function in the ileum from bile acid-driven oxidative stress and MDR1 loss of function in a subset of patients with Crohn's disease. However, the role of consumption of fatty acids in Crohn's disease remains to be fully elucidated. This review is aimed at providing an overview of some recent developments in research of Crohn's disease from comprehensive perspective with a focus on the connection between disease location and behaviour, lipid diets, and bile acid malabsorption.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Disease location at diagnosis and at elapsed years among patients with Crohn's disease in a study of the University Hospital of Liège in Belgium [11].
Figure 2
Figure 2
Disease location at recruitment and after 5 years among patients with Crohn's disease in a study in southeastern Norway [12].
Figure 3
Figure 3
Disease location at diagnosis and after 7 years among patients with Crohn's disease in a study of a Danish cohort [10].

Similar articles

Cited by

References

    1. The International IBD Genetics Consortium (IIBDGC), Jostins L., Ripke S., et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature. 2012;491(7422):119–124. doi: 10.1038/nature11582. - DOI - PMC - PubMed
    1. Abraham C., Cho J. H. Inflammatory bowel disease. New England Journal of Medicine. 2009;361(21):2066–2078. doi: 10.1056/NEJMra0804647. - DOI - PMC - PubMed
    1. Burisch J., Pedersen N., Cukovic-Cavka S., et al. Environmental factors in a population-based inception cohort of inflammatory bowel disease patients in Europe—an ECCO-EpiCom study. Journal of Crohn's and Colitis. 2014;8(7):607–616. doi: 10.1016/j.crohns.2013.11.021. - DOI - PubMed
    1. Ruemmele F. M., Veres G., Kolho K. L., et al. Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn’s disease. Journal of Crohn's and Colitis. 2014;8(10):1179–1207. doi: 10.1016/j.crohns.2014.04.005. - DOI - PubMed
    1. On Behalf of the Guidelines Project Group of the Research Group of Intractable Inflammatory Bowel Disease subsidized by the Ministry of Health, Labour and Welfare of Japan and the Guidelines Committee of the Japanese Society of Gastroenterology, Ueno F., et al. Evidence-based clinical practice guidelines for Crohn’s disease, integrated with formal consensus of experts in Japan. Journal of Gastroenterology. 2013;48(1):31–72. doi: 10.1007/s00535-012-0673-1. - DOI - PMC - PubMed

Substances